SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Top Headlines

Mannkind looks to Sanofi for secondary supply of inhalable insulin API

Mannkind looks to Sanofi for secondary supply of inhalable insulin API

Mannkind says Sanofi could become a second API supplier for its recently approved inhalable insulin drug Afrezza following its commercialisation partnership last month.

Related news

News in brief

Gilead has granted seven Indian drugmakers licenses to produce generic versions of its $1,000 a pill drug Sovaldi to increase access to hepatitis C medicines in 91 developing countries.

The UK’s NICE says it will go over drug companies’ heads and get clinical trial data from regulators if sponsors fail to supply their results.

As the EMA has announced that the main objectives of its pharmacovigilance legislation are largely being achieved , the agency is still implementing a number of the individual modules that make up the over-arching law.

Almac’s subsidiary Galen has licensed UK sales and marketing rights to an emergency pain drug nicknamed the “green whistle” from Australian firm Medical Developments International (MVP).

Global Industry News

CRL on the prowl for Chinese M&As in world’s future science hub from BioPharma-Reporter.com

Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region.

Almac teams with Welsh academics to create P450 enzymes for industry from Outsourcing-Pharma.com

Almac has teamed up with Welsh Academics and industrial chemistry firm Hockley International to develop enzymes capable of making drug intermediates more quickly.

DHL and Octopharma open cold-chain logistics centre in Germany from Outsourcing-Pharma.com

In a venture with plasma products manufacturer Octopharma, DHL has opened a €3.4m ($4.4m) cold-chain logistics centre in Germany for the pharma and life sciences industries.

Earn Billions: Learn how at BioPharma-Reporter.com’s Biosimilars forum from BioPharma-Reporter.com

Either the folks at Hospira, Celltrion, Samsung Biologics, Teva, Merck & Co and Quintiles are hopeless romantics investing in science for its own sake or, for them, the “debate” about the potential of the biosimilars market has already been resolved.   

Roche: Counterfeit MabThera discovered in Germany from BioPharma-Reporter.com

A German parallel importer has informed Roche that counterfeit versions of its cancer treatment MabThera (rituximab) have been discovered in Germany.

Parexel adds two clinical tech companies to partner program from Outsourcing-Pharma.com

CRO (contract research organization) Parexel International has allowed clinical technology companies CRF Health and Clinical Ink to join its Perceptive Partner Program. 

Spotlight

Ben venue fallout continues to cause headache for Boehringer Ingelheim

Ben venue fallout continues to cause headache for Boehringer Ingelheim

Divested sterile manufacturer Ben Venue has continued to cause trouble for Boehringer Ingelheim with a second recall...

‘James bond’-like tech is the end to overdoses, says formulation firm

‘James bond’-like tech is the end to overdoses, says formulation firm

Canadian drugmaker Intellipharmaceutics has developed a kill-switch formulation it says will prevent drug misuse and accidental overdoses.

Find other oral forms for tablet-hating patients, drugmakers told

Find other oral forms for tablet-hating patients, drugmakers told

Pharma firms must provide imaginative solid dosage alternatives to tablets and capsules, says research claiming more than...

Gangsters imported fake drugs from Asia says Europol

Gangsters imported fake drugs from Asia says Europol

Millions of fake pharmaceuticals seized earlier today were imported from Asia by an organised crime group that...

Compounding the problem: US warns two more pharmacies

Compounding the problem: US warns two more pharmacies

The US FDA has criticised the Compounding Shop and Zion Rx Formulations Services for making unapproved and...

Is Pfizer now eyeing up Actavis three months after failed AZ bid?
INFOGRAPHIC

Is Pfizer now eyeing up Actavis three months after failed AZ bid?

Pfizer is rumoured to be eyeing up Actavis three months after failing to woo AstraZeneca in a...

Key Industry Events

 

Access all events listing

Our events, Events from partners...